Cancer is an abnormal growth and proliferation of cells. It is a frightful disease because the patient suffers pain, disfigurement and loss of many physiological processes. Cancer may be uncontrollable and incurable, and may occur at any time at any age in any part of the body. It is caused by a complex; poorly understood interplay of genetic and environmental factors. Cancer is the second leading cause of death economically developed countries and the third in emergent nations. Lung cancer is a second leading cause of death in worldwide accounting for 1.59 million deaths in 2012. It’s a cause of morbidity and mortality among men and women. That’s followed by two types of lung cancer. Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC); non-small cell lung cancer is much more common and accounts for 75-85% causes of all lung cancers. Mutations in the EGFR kinase are a cause of non-small cell lung cancer. Epidermal growth factor receptor (EGFR), is a receptor tyrosine kinase which is frequently over-expressed in non-small cell lung cancer. This receptor plays an important role in tumors cell survival and activated phosphorylated EGFR results in the phosphorylation of downstream proteins that cause cell proliferation, invasion, metastasis and inhibition of apoptosis. Expression appears to be dependent on histological subtypes, most frequently expressed in squamous cell carcinoma but also frequently expressed in adenocarcinomas and large cell carcinoma. EGFR including more than 75-85 % of non-small cell lung cancers, it was one of the first molecules to be selected for the development of targeted therapies. The receptor belongs to the ErbB/HER family of ligand-activated RTKs, which includes four structurally similar members EGFR/HER1, ErbB2/HER2, ErbB3 / HER3 and ErbB4/HER4, has been clinically validated as a leading approach to selectively target cancer cells. Mutant receptor has been reported in many cell types such as gliomas, non-small cell lung cancer, prostate, breast, ovary and stomach cancer. Currently two small molecule kinase inhibitors, ZD1839 (Iressa) and OSI774 (Tarceva), are in clinical use for the treatment of lung cancer. There are more than ten EGFR inhibitors currently being tested in clinical trials. Among them there are several covalent inhibitors such as HKI-357, HKI-272, EKB569, IBIBW2992 and PF2998044 which target a unique cysteine 797 residue located at the lip of the EGFR ATP binding site. The development of specific antagonists targeting the EGFR has proved to be a promising therapeutic concept. There are two classes of EGFR antagonists which have been used in clinic: anti-EGFR monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitor (TKIs). During the past two decades, a lot of compounds with different skeletons were reported as EGFR TKIs, such as 4-anilinoquinoline-3- arbonitriles, 1H-pyrazolo [3, 4-d] pyrimidines, pyrrolotriaazines, 4-amino-6-arylaminoopyrimidines and thienopyrimidine. The 4-(phenylmethyl) amino and 4-(3 bromophenyl) amino were evaluated for their inhibitory activities against EGFR tyrosine kinases that led to some interesting findings on structure activity relationships of these compounds. Considering EGFR is a rational target for antitumor strategies, one of the most important methods to inhibit EGFR is to block tyrosine kinase at ATP-binding site in cytoplasmic domain by small-molecule inhibitors. The representative frame of inhibitor is 4-anilinoquinazolines, such as gefitinib (ZD-
The leaves of plant sample were washed with tap water. Preparation of Sample

Screening (VS) studies were performed by using the docking approach. The great pharmacological importance of the TIAs associated with the low abundance of the anticancer drugs in the plant (around 0.0005 % DW)\(^3\). \textit{In-silico} screening is one of the most convenient methods to evaluate millions of molecules and obtain novel compounds. In the last few years, \textit{In-Silico} Virtual Screening (VS) studies were performed by using the docking approach\(^4,5\). In this work for \textit{C. roseus} leaves methanolic extract was identified by GC-MS analysis. The structure of the compound was retrieved from Pubchem. The retrieved compounds are performed to \textit{in silico} docking study (Protein- Ligand interaction) by Discover Studio Version 4.0 (Accelry’s Software Inc. USA). The higher docking energy values are good binding energy and hence more efficient in blocking the activity of the particular protein\(^6\).

**MATERIAL AND METHODS**

**Collection of Plant Samples**

The leaves of \textit{Catharanthus roseus} samples were collected from Karunguzhi (village), Cuddalore district, Tamil Nadu, India. This plant was collected in the morning session (during 8am- 10am) and packed polyethylene bag. The sample were transported to the Laboratory in Annamalai University and kept at room temperature for this processing; the Herbarium accession number 272, identified in Department of Botany, Annamalai University, Chidambaram, India

**Preparation of Sample**

The leaves of plant sample were washed with tap water and dried under room temperature for 10 days. Approximately about 100 g of leaves were ground using a heavy duty grinder for 15 sec. The dry samples were homogenized in grinder for 3 min to mesh size. The air dried leaves of \textit{C. roseus} were pulverized into powdered form.

**Extraction of Leaves**

The powder leaves of \textit{C. roseus} (100 g) were extracted with methanol (500 ml) with 48 hours at temperature between 60-65°C by using soxhlet extractor. The solvent was evaporated by evaporator to obtained viscous semi solid masses. The semi dry methanol crude extract 30 g was suspended in water. The crude extract was filtered separately through whatman No: 4, filter paper to obtain dust free plant crude extract. This extract were concentrated and dried by using rotary evaporator under the vacuum.

**GC-MS Analysis**

The GC-MS analysis of organic methanol extracts isolated from leaves \textit{C. roseus} were carried out. Helium was used as the carrier gas at a flow rate of 1 ml/min. The temperature was programmed at a flow rate of 1ml/min. The temperature was programmed at 80°C for 5 min then increased up to 300°C at the rate of 15°C/min. The temperature of injector and E1 detector (70ev) was 280°C and 300°C, respectively 2 μl of plant extract was injected with GC-MS manually.

**Preparation of protein structure**

The structural information of the macromolecules determined by x-ray crystallographic and NMR methods are available in the PDB. The 3D structure Epidermal Growth Factor Receptor (PDB 1D: 2ITO) was downloaded from the Protein Data Bank (PDB) (http://www.rcsb.org/pdb/). The water molecules were removed from protein file 2ITO before docking. Energy minimization was done by applying for CHARMM (Chemistry at HARvard Macromolecular Mechanics) force fields, It’s a program for macromolecular dynamics; it can be used for energy minimization, normal modes and crystal optimizations and also incorporates free energy methods for chemical and conformational free energy calculations.

**Preparation of Ligand structures**

The identified Chemical compounds namely 4-piperidineacetic,1-acetyl-5-ethyl-2- [3-[2-hydroxyethyl]-1H-indol-2-yl]-a-methyl, methyl ester and 2H-Pyan,tetrahydro-2-[12-pentadecynloxy] was derived from \textit{Catharanthus roseus} plant leaves and these compound structure were retrieved from Pubchem online server. Both of these compounds were under investigation of Chem Sketch (Chemically intelligent drawing interface free were developed by Advance Chemistry Development, Inc., (http://www.acdlabs.com) chem sketch was used to construct the structure of the ligands. The ligand molecules were generated and the three dimensional optimizations were done and then saved as MOL file (a file format for holding information about the
atoms, bonds, connectivity and coordinates of a molecule).

**Docking analysis**

The docking analysis was performed by Discover Studio Version 4.0 (Accelry’s Software Inc. USA) for the EGFR non-small cell lung cancer protein interaction with GC-MS of *Catharanthus roseus* leaves extract compounds. Fitting points were added to hydrogen bonding groups on the protein. The interaction between the binding pockets of target EGFR protein and investigation compound was to find out the accurate binding model for the active site of protein. The mechanism of ligand placement was based on binding site position. The protein ligand docking energy values performance of the 5 compounds was based on the Scoring functions which is implemented in docking program to make various assumptions and simplifications to fit best complexes, which includes terms of hydrogen bonds employed by Discovery Studio to rank the docked bases and to assess the binding site and the number of rotatable bonds present.

**RESULTS**

The methanol extract of *Catharanthus roseus* plant leaves (Figure 1) was analyzed by GC-MS and these compounds was identified from the sample using Helium at 280°C-300°C. Based on the results of GC-MS analysis Retention Time (RT) peaks (Figure 2) five compounds was identified from extract of *C. roseus* leaves extract. These five compounds are namely (RT = 14.97) Corynan-17-ol, 18, 19-didehydro-10-methoxyacetate [ester], (RT = 16.22) 4-piperidineacetec,1-acetyl-5-ethyl-2-[3-[2-hydroxyethyl]-1H-indol-2-yl]-a-methyl-methyl ester, (RT = 17.47) 2H-Pyran, tetrahydro-2-12-pentadecynloxy], (RT=17.8) 2H-Pyran-2-one, tetrahydro-6-nonyl-, and (RT = 19.15) Cholestan-3-ol,2-methylene. Compounds 2D structure and its properties were shown in Table 1. The Epidermal Growth Factor Receptor (EGFR) responsible for non-small cell lung cancer (NSCLC) protein structure (Figure 3) was retrieved from PDB. The extracted two compounds were docked with EGFR protein. From these two compounds which exhibit higher lib dock score values were noted. The Compound (A) 4-piperidineacetec, 1-acetyl-5-ethyl-2-[3-[2-hydroxyethyl]-1H-indol-2-yl]-a methyl ethyl ester (Figure 4) interacts with EGFR protein, it formed 4 hydrogen interactions between the target and Libdock score value was 112.10 (Figure 5). The compound (B) 2H-Pyran, tetrahydro-2-12-pentadecynloxy] (Figure 6) interacts with EGFR formed one hydrogen bonding and Libdock score value was 106.2 (Figure 7). From above findings the compound A exhibit highest Libdock score.
Table 1: Properties of chemical compounds

<table>
<thead>
<tr>
<th>Compound Name</th>
<th>Compound ID</th>
<th>Molecular Formula</th>
<th>Molecular Weight [g/mol]</th>
<th>Compound Structure</th>
<th>Hydrogen Donor and Acceptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corynan-17-ol, 18, 19-didehydro-10-methoxy-, acetate (ester)</td>
<td>550058</td>
<td>C_{22}H_{28}N_{2}O_{3}</td>
<td>368.46932</td>
<td><img src="image" alt="Structure" /></td>
<td>1,4</td>
</tr>
<tr>
<td>4-piperidineacetic, 1-acetyl-5-ethyl-2-[3-[2-hydroxyethyl]-1H-indol-2-yl]-a-methyl-methyl ester.</td>
<td>5379474</td>
<td>C_{22}H_{28}N_{2}O_{4}</td>
<td>396.47942</td>
<td><img src="image" alt="Structure" /></td>
<td>2,4</td>
</tr>
<tr>
<td>2H-Pyran, tetrahydro-2-[12-pentadecynoxy]</td>
<td>41961</td>
<td>C_{20}H_{36}O_{2}</td>
<td>308.49864</td>
<td><img src="image" alt="Structure" /></td>
<td>0,2</td>
</tr>
<tr>
<td>2H-Pyran-2-one, tetrahydro-6-nonyl-</td>
<td>520296</td>
<td>C_{14}H_{26}O_{2}</td>
<td>226.35504</td>
<td><img src="image" alt="Structure" /></td>
<td>0,2</td>
</tr>
<tr>
<td>Cholestan-3-ol, 2-methylene, (3a, 5a).</td>
<td>3240</td>
<td>C_{27}H_{48}O</td>
<td>388.66942</td>
<td><img src="image" alt="Structure" /></td>
<td>1,1</td>
</tr>
</tbody>
</table>

Figure 3: Crystal structure of EGFR protein

Figure 4: Structure of 4-piperidineacetic, 1-acetyl-5-ethyl-2-[3-[2-hydroxyethyl]-1H-indol-2-yl]-a-methyl-, methyl ester
DISCUSSION

Natural source are increasingly used in identification of new medicinal agents which are important for many clinical purposes. Molecular docking is important methods in computerized drug designing for targeted disease. Herbalism has a long tradition of use of outside of conventional medicine. It is becoming now more as main stream due to improvements in analysis and quality control along with advances in clinical research. *Catharanthus roseus* commonly called Madagascar periwinkle is herbaceous plant which exhibits the anti-cancer activity. This plant produces a diverse array of secondary metabolites that are pharmaceutically important and used as chemotherapeutic agents in the treatment of several types of cancers. This study was structure-based drug design for Non-Small Cell lung cancer. *In Silico* technique strongly supports and helps to identify the novel and more potent inhibitors through the mechanism of Ligand-Receptor interaction. Many drugs are available for clinically non-small cell lung cancer (NSCLC). Here we used GC-MS analysis of extraction of *Catharanthus roseus* plant leaves for inhibiting NSCLC responsible protein. The new investigation of 4-piperidineacetac, 1-acetyl-5-ethyl-2-[3-[2-hydroxyethyl]-1H-indol-2-yl]-a-methyl-methyl ester compound was higher with stronger binding affinity and hydrogen bond interactions. There are 4 hydrogen bond interactions results with corresponding amino residues for LYS-745, ASN-842, ASP-855, GLY-857 and libdock score value was 112.106. The present *In-silico* docking study proves the *Catharanthus roseus* plant leaves extract compounds as higher libdock score value to inhibit the epidermal growth factor receptor (EGFR) responsible for non-small cell lung cancer. Our previous research has already proved that marine source phytochemicals are used as drug for blocking BRCA1 Breast cancer protein. Always natural source are eco-friendly and less side effects. Our present study suggest that *Catharanthus roseus* plant leaves extract compounds are potential drug for inhibiting non-small cell lung cancer.

ACKNOWLEDGEMENTS

Authors are thankful to the authorities of Annamalai University UGC-SAP Sponsored for providing necessary facilities to carry out this work.

REFERENCES

1. Loose DS, GM Stancel, Estrogens, progestins; In Goodman and Gilman’s the Pharmacological Basis of Therapeutics 2006; 11: 1541-1571.


Senthilraja P et al / Int. J. Res. Ayurveda Pharm. 6(2), Mar - Apr 2015


Cite this article as:

Source of support: Annamalai University UGC-SAP, Conflict of interest: None Declared